{
    "clinical_study": {
        "@rank": "60422", 
        "acronym": "EMPRES", 
        "arm_group": [
            {
                "arm_group_label": "Exenatide", 
                "arm_group_type": "Experimental", 
                "description": "o Exenatide at a dose of 1.5 \u00b5g IV over 30 min followed by 1.2 \u00b5g/hr IV for 1.5 h (Rate1), followed by 1.9 \u00b5g/hr IV* for 22 h (Rate 2), or\n*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.\nIf the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.\nA bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "o\tPlacebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to assess the effect of exenatide on myocardial injury in patients\n      undergoing emergent percutaneous coronary intervention (PCI) for ST segment elevation\n      myocardial infarction or heart attack (STEMI)."
        }, 
        "brief_title": "Exenatide for Myocardial Protection During Reperfusion Study", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase II randomized, double-blind, placebo-controlled study of patients with\n      STEMI. Those who agree to participate will be immediately randomized to one of two groups: a\n      24-h infusion of exenatide; or a 24 h infusion of placebo. We will assess the ability of\n      exenatide to reduce ischemic injury. This study will serve as safety evaluation study as\n      well as a pilot for a larger multicentre trial powered for clinical outcomes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Admission for primary PCI for STEMI within 12 hours of onset of symptoms. STEMI will\n             be defined as typical ECG changes (ST segment elevation \u22651mm in 2 or more limb leads,\n             or \u22652mm in 2 or more precordial leads, or new onset LBBB) associated with acute chest\n             pain or an elevation of cardiac enzymes. For non-anterior MI: ST-segment elevation =\n             1mm in 2 or more limb leads and at least one of the following high-risk\n             characteristics: systolic blood pressure < 100 mm Hg, heart rate > 100 bpm, Killip\n             class II or III, ST-segment depression \u2265 2 mm in the anterior leads, or ST-segment\n             elevation \u2265 1 mm in right-sided lead V4 (V4R)\n\n          -  Antegrade TIMI 0 or 1 prior to PCI in the infarct-related artery\n\n          -  Age \u226518 years\n\n        Exclusion Criteria:\n\n          -  Symptomatic hypoglycemia (serum glucose  <3.3 \u00b5mol/L; 60 mg/dl)\n\n          -  Diabetes mellitus requiring insulin therapy\n\n          -  Diabetic ketoacidosis\n\n          -  Coronary anatomy warranting emergent coronary artery bypass graft surgery\n\n          -  Mechanical complication of STEMI (ventricular septal rupture, free wall rupture,\n             acute severe mitral regurgitation)\n\n          -  Need for hemodialysis\n\n          -  Malignancy, HIV, or central nervous system disorder\n\n          -  Cardiopulmonary resuscitation >15 min and compromised level of consciousness.\n\n          -  Cardiogenic shock\n\n          -  Current participation in any research study involving investigational drugs or\n             devices\n\n          -  Inability to give informed consent\n\n          -  Inability to safely undergo cMRI (presence of cardiac pacemaker, implanted cardiac\n             defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator,\n             implanted drug infusion device, bone growth/fusion stimulator, cochlear, otologic, or\n             ear implant, severe claustrophobia)\n\n          -  Women of childbearing potential who are known to be pregnant or lactating or who have\n             a positive pregnancy test on admission\n\n          -  History of pancreatitis\n\n          -  Known end stage renal failure or known eGFR <30 mL/min\n\n          -  Currently taking exenatide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938235", 
            "org_study_id": "MB001-001", 
            "secondary_id": "9427-D0416-21C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exenatide", 
                "description": "Intravenous bolus and 24-hour infusion of exenatide", 
                "intervention_name": "Exenatide", 
                "intervention_type": "Drug", 
                "other_name": "Byetta"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Exenatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Myocardial infarction", 
            "Percutaneous coronary intervention", 
            "Reperfusion injury", 
            "Exenatide", 
            "Magnetic resonance imaging"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "University Health Network, Toronto General Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "University Health Network"
                }, 
                "investigator": {
                    "last_name": "Vladimir Dzavik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial", 
        "overall_contact": {
            "email": "panzovV@smh.ca", 
            "last_name": "Val Panzov, MD", 
            "phone": "416-864-6060", 
            "phone_ext": "7125"
        }, 
        "overall_contact_backup": {
            "email": "giamoum@smh.ca", 
            "last_name": "Melissa Giamou, BSc", 
            "phone": "416-864-6060", 
            "phone_ext": "7889"
        }, 
        "overall_official": {
            "affiliation": "University Health Network, Toronto", 
            "last_name": "Vladimir Dzavik, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI)", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938235"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Health Network, Toronto", 
            "investigator_full_name": "Vlad Dzavik", 
            "investigator_title": "Deputy Head, Division of Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Left ventricular global and regional LV systolic ejection fraction", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Left ventricular global and regional LV systolic ejection fraction", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Left ventricular volume", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Left ventricular volume", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Infarct size/area of risk (measured by cMRI)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Myocardial enzyme levels (troponin I and CK-MB)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "ST segment elevation resolution (measured by ECG)", 
                "safety_issue": "No", 
                "time_frame": "1 hour"
            }, 
            {
                "measure": "ST segment elevation resolution (measured by ECG)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "ST segment elevation resolution (measured by ECG)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "ST segment elevation resolution (measured by ECG)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Angiographic myocardial blush score", 
                "safety_issue": "No", 
                "time_frame": "At the time of the PCI procedure"
            }, 
            {
                "measure": "Serum glucose concentration", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Serum glucose concentration", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Glucose blood concentration (measured with point-of-care device)", 
                "safety_issue": "No", 
                "time_frame": "Every 2 hours for 24 hours post-PCI procedure"
            }, 
            {
                "measure": "Inflammatory marker levels (interleukin-6, IL-10, TNF-alpha)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Inflammatory cell activation (neutrophil phagocytosis, chemotaxis, superoxide production)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Inflammatory cell activation (neutrophil phagocytosis, chemotaxis, superoxide production)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "NT-proBNP blood levels", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Myocardial infarction (heart attack)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Measure of extent of heart failure (NYHA classification)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Measure of extent of heart failure (NYHA classification)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Major adverse cardiac events (defined as a combined outcome of death, recurrent myocardial infarction, stroke, and unplanned repeat revascularization)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Recurrent myocardial infarction (heart attack)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Stroke", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Unplanned repeat revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Development of heart failure", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Cardiogenic shock", 
                "safety_issue": "Yes", 
                "time_frame": "During index hospitalization (up to 6 months)"
            }, 
            {
                "measure": "Blood glucose < 3.0 mmol/L", 
                "safety_issue": "Yes", 
                "time_frame": "During index hospitalization (up to 6 months)"
            }, 
            {
                "measure": "Hypotension (defined as SBP <90 mmHg)", 
                "safety_issue": "Yes", 
                "time_frame": "During index hospitalization (up to 6 months)"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}